High-grade mature B-cell lymphoma with Burkitt-like morphology: Results of a clinicopathological study of 72 Japanese patients

Yuko Nomura, Kennosuke Karube, Ritsuro Suzuki, Guo Ying, Morishige Takeshita, Shinichi Hirose, Nhigeo Nakamura, Tadashi Yoshino, Masahiro Kikuchi, Koichi Ohshima

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients. We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases. On clinical and immunophenotypic analysis, the typical BL immunophenotype (CD10 positive, bcl-2 negative, and Ki-67 index ≥95%) was noted in 23 (66%) and 11 (55%) of the 35 mBL and 20 mBL-like patients, respectively. The presence of the c-myc translocation and typical immunophenotype in BL did not affect the overall survival of BL/ BLL. There were no significant differences between the overall survival of DLBCL (45%) and BL/BLL (50%, P = 0.85). However, the overall survival of BL/BLL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy (22%) was significantly lower than that of DLBCL patients (P = 0.01). In contrast, the overall survival of BL/BLL patients who received aggressive short-term chemotherapy (75%) was better than that of the patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy (P <0.01). The finding was confirmed by multivariate analysis (hazard ratio 4.4; confidence interval 2.0-9.7; P = 0.0003). We concluded that aggressive short-term chemotherapy improves survival in BL/BLL, regardless of its genetic and immunophenotypic features.

Original languageEnglish
Pages (from-to)246-252
Number of pages7
JournalCancer Science
Volume99
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Burkitt Lymphoma
B-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Survival
Vincristine
Prednisolone
Doxorubicin
Cyclophosphamide
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-grade mature B-cell lymphoma with Burkitt-like morphology : Results of a clinicopathological study of 72 Japanese patients. / Nomura, Yuko; Karube, Kennosuke; Suzuki, Ritsuro; Ying, Guo; Takeshita, Morishige; Hirose, Shinichi; Nakamura, Nhigeo; Yoshino, Tadashi; Kikuchi, Masahiro; Ohshima, Koichi.

In: Cancer Science, Vol. 99, No. 2, 02.2008, p. 246-252.

Research output: Contribution to journalArticle

Nomura, Y, Karube, K, Suzuki, R, Ying, G, Takeshita, M, Hirose, S, Nakamura, N, Yoshino, T, Kikuchi, M & Ohshima, K 2008, 'High-grade mature B-cell lymphoma with Burkitt-like morphology: Results of a clinicopathological study of 72 Japanese patients', Cancer Science, vol. 99, no. 2, pp. 246-252. https://doi.org/10.1111/j.1349-7006.2007.00681.x
Nomura, Yuko ; Karube, Kennosuke ; Suzuki, Ritsuro ; Ying, Guo ; Takeshita, Morishige ; Hirose, Shinichi ; Nakamura, Nhigeo ; Yoshino, Tadashi ; Kikuchi, Masahiro ; Ohshima, Koichi. / High-grade mature B-cell lymphoma with Burkitt-like morphology : Results of a clinicopathological study of 72 Japanese patients. In: Cancer Science. 2008 ; Vol. 99, No. 2. pp. 246-252.
@article{56e085ff5351407f9e6c4268dce7e810,
title = "High-grade mature B-cell lymphoma with Burkitt-like morphology: Results of a clinicopathological study of 72 Japanese patients",
abstract = "The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients. We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases. On clinical and immunophenotypic analysis, the typical BL immunophenotype (CD10 positive, bcl-2 negative, and Ki-67 index ≥95{\%}) was noted in 23 (66{\%}) and 11 (55{\%}) of the 35 mBL and 20 mBL-like patients, respectively. The presence of the c-myc translocation and typical immunophenotype in BL did not affect the overall survival of BL/ BLL. There were no significant differences between the overall survival of DLBCL (45{\%}) and BL/BLL (50{\%}, P = 0.85). However, the overall survival of BL/BLL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy (22{\%}) was significantly lower than that of DLBCL patients (P = 0.01). In contrast, the overall survival of BL/BLL patients who received aggressive short-term chemotherapy (75{\%}) was better than that of the patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy (P <0.01). The finding was confirmed by multivariate analysis (hazard ratio 4.4; confidence interval 2.0-9.7; P = 0.0003). We concluded that aggressive short-term chemotherapy improves survival in BL/BLL, regardless of its genetic and immunophenotypic features.",
author = "Yuko Nomura and Kennosuke Karube and Ritsuro Suzuki and Guo Ying and Morishige Takeshita and Shinichi Hirose and Nhigeo Nakamura and Tadashi Yoshino and Masahiro Kikuchi and Koichi Ohshima",
year = "2008",
month = "2",
doi = "10.1111/j.1349-7006.2007.00681.x",
language = "English",
volume = "99",
pages = "246--252",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - High-grade mature B-cell lymphoma with Burkitt-like morphology

T2 - Results of a clinicopathological study of 72 Japanese patients

AU - Nomura, Yuko

AU - Karube, Kennosuke

AU - Suzuki, Ritsuro

AU - Ying, Guo

AU - Takeshita, Morishige

AU - Hirose, Shinichi

AU - Nakamura, Nhigeo

AU - Yoshino, Tadashi

AU - Kikuchi, Masahiro

AU - Ohshima, Koichi

PY - 2008/2

Y1 - 2008/2

N2 - The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients. We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases. On clinical and immunophenotypic analysis, the typical BL immunophenotype (CD10 positive, bcl-2 negative, and Ki-67 index ≥95%) was noted in 23 (66%) and 11 (55%) of the 35 mBL and 20 mBL-like patients, respectively. The presence of the c-myc translocation and typical immunophenotype in BL did not affect the overall survival of BL/ BLL. There were no significant differences between the overall survival of DLBCL (45%) and BL/BLL (50%, P = 0.85). However, the overall survival of BL/BLL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy (22%) was significantly lower than that of DLBCL patients (P = 0.01). In contrast, the overall survival of BL/BLL patients who received aggressive short-term chemotherapy (75%) was better than that of the patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy (P <0.01). The finding was confirmed by multivariate analysis (hazard ratio 4.4; confidence interval 2.0-9.7; P = 0.0003). We concluded that aggressive short-term chemotherapy improves survival in BL/BLL, regardless of its genetic and immunophenotypic features.

AB - The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients. We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases. On clinical and immunophenotypic analysis, the typical BL immunophenotype (CD10 positive, bcl-2 negative, and Ki-67 index ≥95%) was noted in 23 (66%) and 11 (55%) of the 35 mBL and 20 mBL-like patients, respectively. The presence of the c-myc translocation and typical immunophenotype in BL did not affect the overall survival of BL/ BLL. There were no significant differences between the overall survival of DLBCL (45%) and BL/BLL (50%, P = 0.85). However, the overall survival of BL/BLL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy (22%) was significantly lower than that of DLBCL patients (P = 0.01). In contrast, the overall survival of BL/BLL patients who received aggressive short-term chemotherapy (75%) was better than that of the patients who received cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy (P <0.01). The finding was confirmed by multivariate analysis (hazard ratio 4.4; confidence interval 2.0-9.7; P = 0.0003). We concluded that aggressive short-term chemotherapy improves survival in BL/BLL, regardless of its genetic and immunophenotypic features.

UR - http://www.scopus.com/inward/record.url?scp=38949176013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949176013&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00681.x

DO - 10.1111/j.1349-7006.2007.00681.x

M3 - Article

C2 - 18271922

AN - SCOPUS:38949176013

VL - 99

SP - 246

EP - 252

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -